

EXHIBIT 5

From: Kayali, Kathryn <KKayali@wc.com>
Sent: Tuesday, June 11, 2024 10:09 PM
To: Brett A. Postal; Neil B. McLaughlin; Aviv Zalcenstein; Robert Oakes; Laura Fairneny; Terri Mascherin
Cc: Patel, Priyata; Mike Cottler; Shaun Van Horn; John R. Labbe; Argall, Arthur; M710 Team; Jamie.Obrien@steptoe-johnson.com; Gordon.Copland@steptoe-johnson.com; DG-Aflibercept; WFG-aflibercept@willkie.com; mhissam@hfdrlaw.com; Carl Shaffer; Andrew Robey; Max Gottlieb; QE - Samsung Bioepis; skl@schraderlaw.com; clt@simmermanlaw.com; fes@simmermanlaw.com; trey@simmermanlaw.com; SERVICE - Formycon Team; MGB-Amgen-ABP938; ABP938; REGENERONPATENT@lists.kelloggghansen.com; drpogue@cdkrlaw.com; sruby@cdkrlaw.com; Ashley Hardesty Odell; Kaitlyn McKitrick; Eylea.Biosimilars@weil.com; Eylea
Subject: RE: In re aflibercept - May 10 submission m/c
Attachments: RGN Edits - Draft Joint Proposed Order re Redacted Versions of Sealed Filings June 4 2024 (002).docx

Brett:

Please find Regeneron's proposed revisions to the stipulation attached. Regeneron maintains that modification of the existing protective orders is appropriate irrespective of these changes.

Best,

Kat

Kathryn S. Kayali
Williams & Connolly LLP
680 Maine Avenue S.W., Washington, DC 20024
(P) 202-434-5644 | (F) 202-434-5029
kkayali@wc.com | www.wc.com

From: Brett A. Postal <bpostal@rothwellfigg.com>
Sent: Monday, June 10, 2024 3:22 PM
To: Neil B. McLaughlin <NMcLaughlin@rmmslegal.com>; Kayali, Kathryn <KKayali@wc.com>; Aviv Zalcenstein <azalcenstein@geminilaw.com>; Robert Oakes <RMO@FR.com>; Laura Fairneny <laurafairneny@quinnemanuel.com>; Terri Mascherin <tmascherin@jenner.com>
Cc: Patel, Priyata <Priyata.Patel@weil.com>; Mike Cottler <mcottler@geminilaw.com>; Shaun Van Horn <vanhorn@fr.com>; John R. Labbe <jabbe@marshallip.com>; Argall, Arthur <aargall@wc.com>; M710 Team <M710Team@rmmslegal.com>; Jamie.Obrien@steptoe-johnson.com; Gordon.Copland@steptoe-johnson.com; DG-Aflibercept <DG-Aflibercept@NETORG8512690.onmicrosoft.com>; WFG-aflibercept@willkie.com; mhissam@hfdrlaw.com; Carl Shaffer <cshaffer@hfdrlaw.com>; Andrew Robey <arobey@hfdrlaw.com>; Max Gottlieb <mgottlieb@hfdrlaw.com>; QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; skl@schraderlaw.com; clt@simmermanlaw.com;

fes@simmermanlaw.com; trey@simmermanlaw.com; SERVICE - Formycon Team <SERVICE-Formycon_Team@fr.com>; MGB-Amgen-ABP938 <MGB-Amgen-ABP938@marshallip.com>; ABP938 <ABP938@rothwellfigg.com>; REGENERONPATENT@lists.kellogghansen.com; drpogue@cdkrlaw.com; sruby@cdkrlaw.com; Ashley Hardesty Odell <ahardestyodell@bowlesrice.com>; Kaitlyn McKitrick <kmckitrick@bowlesrice.com>; Eylea.Biosimilars@weil.com; Eylea <Eylea@wc.com>

Subject: RE: In re aflibercept - May 10 submission m/c

Dear Kat:

During the meet and confer, Regeneron agreed to provide its comments to the Proposed Joint Order that we circulated on June 4, 2024. Please provide us with Regeneron's comments no later than tomorrow, June 11.

Thanks,
Brett



Brett A. Postal

901 New York Avenue, NW
Suite 900 East
Washington, D.C. 20001

Main Number: 202.783.6040
Fax Number: 202.783.6031
Email: bpostal@rothwellfigg.com
Website: www.rothwellfigg.com

The information contained in this electronic message and any attachments to this message are intended for the exclusive use of the addressee(s) and may contain confidential and/or privileged information. If you are not the addressee, note that any disclosure, copy, distribution or use of the contents of this message is prohibited. If you are not the intended recipient, please notify Rothwell, Figg, Ernst & Manbeck, P.C. immediately at (202) 783 6040 or email us at bpostal@rfem.com, and destroy all copies of this message and any attachments.

From: Neil B. McLaughlin <NMcLaughlin@rmmslegal.com>

Sent: Monday, June 10, 2024 12:20 AM

To: Brett A. Postal <bpostal@rothwellfigg.com>; Kayali, Kathryn <KKayali@wc.com>; Aviv Zalcenstein <azalcenstein@geminilaw.com>; Robert Oakes <RMO@FR.com>; Laura Fairney <laurafairney@quinnemanuel.com>; Terri Mascherin <tmascherin@jenner.com>

Cc: Patel, Priyata <Priyata.Patel@weil.com>; Mike Cottler <mcottler@geminilaw.com>; Shaun Van Horn <vanhorn@fr.com>; John R. Labbe <jlabbbe@marshallip.com>; Argall, Arthur <aargall@wc.com>; M710 Team <M710Team@rmmslegal.com>; Jamie.Obrien@steptoe-johnson.com; Gordon.Copland@steptoe-johnson.com; DG-Aflibercept <DG-Aflibercept@NETORG8512690.onmicrosoft.com>; WFG-aflibercept@willkie.com; mhissam@hfdrlaw.com; Carl Shaffer <cshaffer@hfdrlaw.com>; Andrew Robey <arobey@hfdrlaw.com>; Max Gottlieb <mgottlieb@hfdrlaw.com>; QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; skl@schraderlaw.com; clt@simmermanlaw.com; fes@simmermanlaw.com; trey@simmermanlaw.com; SERVICE - Formycon Team <SERVICE-Formycon_Team@fr.com>; MGB-Amgen-ABP938 <MGB-Amgen-ABP938@marshallip.com>; ABP938 <ABP938@rothwellfigg.com>; REGENERONPATENT@lists.kellogghansen.com; drpogue@cdkrlaw.com; sruby@cdkrlaw.com; Ashley Hardesty Odell <ahardestyodell@bowlesrice.com>; Kaitlyn McKitrick